Cargando…
Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
Objectives. The purpose of this retrospective evaluation of advanced-stage ovarian cancer patients was to compare outcome with published findings from other centers and to discuss future options for the management of advanced ovarian carcinoma patients. Methods. A retrospective series of 340 patient...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265260/ https://www.ncbi.nlm.nih.gov/pubmed/22312486 http://dx.doi.org/10.1155/2010/214919 |
_version_ | 1782222062392180736 |
---|---|
author | Marszalek, Anne Alran, Séverine Scholl, Suzy Fourchotte, Virginie Plancher, Corinne Rosty, Christophe Meyniel, Jean Philippe De Margerie, Vincent Dorval, Thierry De La Rochefordière, Anne Cottu, Paul Petrow, Peter Sastre-Garrau, Xavier Salmon, Rémy Jacques |
author_facet | Marszalek, Anne Alran, Séverine Scholl, Suzy Fourchotte, Virginie Plancher, Corinne Rosty, Christophe Meyniel, Jean Philippe De Margerie, Vincent Dorval, Thierry De La Rochefordière, Anne Cottu, Paul Petrow, Peter Sastre-Garrau, Xavier Salmon, Rémy Jacques |
author_sort | Marszalek, Anne |
collection | PubMed |
description | Objectives. The purpose of this retrospective evaluation of advanced-stage ovarian cancer patients was to compare outcome with published findings from other centers and to discuss future options for the management of advanced ovarian carcinoma patients. Methods. A retrospective series of 340 patients with a mean age of 58 years (range: 17–88) treated for FIGO stage III and IV ovarian cancer between January 1985 and January 2005 was reviewed. All patients had primary cytoreductive surgery, without extensive bowel, peritoneal, or systematic lymph node resection, thereby allowing initiation of chemotherapy without delay. Chemotherapy consisted of cisplatin-based chemotherapy in combination with alkylating agents before 2000, whereas carboplatin and paclitaxel regimes were generally used after 1999-2000. Overall survival and disease-free survival were analyzed by the Kaplan-Meier method and the log-rank test. Results. With a mean followup of 101 months (range: 5 to 203), 280 events (recurrence or death) were observed and 245 patients (72%) had died. The mortality and morbidity related to surgery were low. The main prognostic factor for overall survival was postoperative residual disease (P < .0002), while the main prognostic factor for disease-free survival was histological tumor type (P < .0007). Multivariate analysis identified three significant risk factors: optimal surgery (RR = 2.2 for suboptimal surgery), menopausal status (RR = 1.47 for postmenopausal women), and presence of a taxane in the chemotherapy combination (RR = 0.72). Conclusion. These results confirm that optimal surgery defined by an appropriate and comprehensive effort at upfront cytoreduction limits morbidity related to the surgical procedure and allows initiation of chemotherapy without any negative impact on survival. The impact of neoadjuvant chemotherapy to improve resectability while lowering the morbidity of the surgical procedure is discussed. |
format | Online Article Text |
id | pubmed-3265260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-32652602012-02-06 Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute Marszalek, Anne Alran, Séverine Scholl, Suzy Fourchotte, Virginie Plancher, Corinne Rosty, Christophe Meyniel, Jean Philippe De Margerie, Vincent Dorval, Thierry De La Rochefordière, Anne Cottu, Paul Petrow, Peter Sastre-Garrau, Xavier Salmon, Rémy Jacques Int J Surg Oncol Clinical Study Objectives. The purpose of this retrospective evaluation of advanced-stage ovarian cancer patients was to compare outcome with published findings from other centers and to discuss future options for the management of advanced ovarian carcinoma patients. Methods. A retrospective series of 340 patients with a mean age of 58 years (range: 17–88) treated for FIGO stage III and IV ovarian cancer between January 1985 and January 2005 was reviewed. All patients had primary cytoreductive surgery, without extensive bowel, peritoneal, or systematic lymph node resection, thereby allowing initiation of chemotherapy without delay. Chemotherapy consisted of cisplatin-based chemotherapy in combination with alkylating agents before 2000, whereas carboplatin and paclitaxel regimes were generally used after 1999-2000. Overall survival and disease-free survival were analyzed by the Kaplan-Meier method and the log-rank test. Results. With a mean followup of 101 months (range: 5 to 203), 280 events (recurrence or death) were observed and 245 patients (72%) had died. The mortality and morbidity related to surgery were low. The main prognostic factor for overall survival was postoperative residual disease (P < .0002), while the main prognostic factor for disease-free survival was histological tumor type (P < .0007). Multivariate analysis identified three significant risk factors: optimal surgery (RR = 2.2 for suboptimal surgery), menopausal status (RR = 1.47 for postmenopausal women), and presence of a taxane in the chemotherapy combination (RR = 0.72). Conclusion. These results confirm that optimal surgery defined by an appropriate and comprehensive effort at upfront cytoreduction limits morbidity related to the surgical procedure and allows initiation of chemotherapy without any negative impact on survival. The impact of neoadjuvant chemotherapy to improve resectability while lowering the morbidity of the surgical procedure is discussed. Hindawi Publishing Corporation 2010 2010-07-25 /pmc/articles/PMC3265260/ /pubmed/22312486 http://dx.doi.org/10.1155/2010/214919 Text en Copyright © 2010 Anne Marszalek et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Marszalek, Anne Alran, Séverine Scholl, Suzy Fourchotte, Virginie Plancher, Corinne Rosty, Christophe Meyniel, Jean Philippe De Margerie, Vincent Dorval, Thierry De La Rochefordière, Anne Cottu, Paul Petrow, Peter Sastre-Garrau, Xavier Salmon, Rémy Jacques Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute |
title | Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute |
title_full | Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute |
title_fullStr | Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute |
title_full_unstemmed | Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute |
title_short | Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute |
title_sort | outcome in advanced ovarian cancer following an appropriate and comprehensive effort at upfront cytoreduction: a twenty-year experience in a single cancer institute |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265260/ https://www.ncbi.nlm.nih.gov/pubmed/22312486 http://dx.doi.org/10.1155/2010/214919 |
work_keys_str_mv | AT marszalekanne outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT alranseverine outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT schollsuzy outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT fourchottevirginie outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT planchercorinne outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT rostychristophe outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT meynieljeanphilippe outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT demargerievincent outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT dorvalthierry outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT delarochefordiereanne outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT cottupaul outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT petrowpeter outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT sastregarrauxavier outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute AT salmonremyjacques outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute |